β-adrenergic blockade in chronic heart failure: Principles, progress, and practice

M. Packer

Research output: Contribution to journalArticle

93 Citations (Scopus)

Abstract

Prolonged activation of the sympathetic nervous system in patients with impaired ventricular function exerts adverse effects on the heart and circulation by a variety of mechanisms that are triggered by the interaction of norepinephrine and epinephrine with α1-, β1-, and β2-adrenergic receptors. Drugs that interfere with the actions of the sympathetic nervous system on α- and β-receptors might be expected to antagonize these deleterious effects. β1-receptor blockers have been shown to prevent and reverse many of the structural and functional changes that occur during the progression of heart failure, and β2- and α1-receptor blockade seems to enhance the ability of β1-blockers to prevent the toxic effects of catecholamines. In a large number of randomized, double-blind, placebo- controlled trials, long-term treatment of patients with chronic heart failure with β-adrenergic blockers improves cardiac function, ameliorates symptoms, and reduces the risk of death and hospitalization. The nature and consistency of these benefits have led an increasing number of physicians to conclude that most patients with heart failure should be considered candidates for long-term treatment with these drugs. Analysis of these clinical trials has also raised the possibility that β-blockers might differ from each other. Specifically, might agents that block α1, β1-, and β2-receptors be more effective and better tolerated that agents that act selectively on the β1- receptor? This hypothesis is now being evaluated in a large-scale, long- term, international trial.

Original languageEnglish (US)
Pages (from-to)39-52
Number of pages14
JournalProgress in Cardiovascular Diseases
Volume41
Issue number1 SUPPL.
StatePublished - 1998

Fingerprint

Adrenergic Agents
Heart Failure
Sympathetic Nervous System
Adrenergic Antagonists
Ventricular Function
Poisons
Pharmaceutical Preparations
Adrenergic Receptors
Epinephrine
Catecholamines
Norepinephrine
Hospitalization
Placebos
Clinical Trials
Physicians
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

β-adrenergic blockade in chronic heart failure : Principles, progress, and practice. / Packer, M.

In: Progress in Cardiovascular Diseases, Vol. 41, No. 1 SUPPL., 1998, p. 39-52.

Research output: Contribution to journalArticle

@article{e2be01509a584810910e9681dd91921a,
title = "β-adrenergic blockade in chronic heart failure: Principles, progress, and practice",
abstract = "Prolonged activation of the sympathetic nervous system in patients with impaired ventricular function exerts adverse effects on the heart and circulation by a variety of mechanisms that are triggered by the interaction of norepinephrine and epinephrine with α1-, β1-, and β2-adrenergic receptors. Drugs that interfere with the actions of the sympathetic nervous system on α- and β-receptors might be expected to antagonize these deleterious effects. β1-receptor blockers have been shown to prevent and reverse many of the structural and functional changes that occur during the progression of heart failure, and β2- and α1-receptor blockade seems to enhance the ability of β1-blockers to prevent the toxic effects of catecholamines. In a large number of randomized, double-blind, placebo- controlled trials, long-term treatment of patients with chronic heart failure with β-adrenergic blockers improves cardiac function, ameliorates symptoms, and reduces the risk of death and hospitalization. The nature and consistency of these benefits have led an increasing number of physicians to conclude that most patients with heart failure should be considered candidates for long-term treatment with these drugs. Analysis of these clinical trials has also raised the possibility that β-blockers might differ from each other. Specifically, might agents that block α1, β1-, and β2-receptors be more effective and better tolerated that agents that act selectively on the β1- receptor? This hypothesis is now being evaluated in a large-scale, long- term, international trial.",
author = "M. Packer",
year = "1998",
language = "English (US)",
volume = "41",
pages = "39--52",
journal = "Progress in Cardiovascular Diseases",
issn = "0033-0620",
publisher = "W.B. Saunders Ltd",
number = "1 SUPPL.",

}

TY - JOUR

T1 - β-adrenergic blockade in chronic heart failure

T2 - Principles, progress, and practice

AU - Packer, M.

PY - 1998

Y1 - 1998

N2 - Prolonged activation of the sympathetic nervous system in patients with impaired ventricular function exerts adverse effects on the heart and circulation by a variety of mechanisms that are triggered by the interaction of norepinephrine and epinephrine with α1-, β1-, and β2-adrenergic receptors. Drugs that interfere with the actions of the sympathetic nervous system on α- and β-receptors might be expected to antagonize these deleterious effects. β1-receptor blockers have been shown to prevent and reverse many of the structural and functional changes that occur during the progression of heart failure, and β2- and α1-receptor blockade seems to enhance the ability of β1-blockers to prevent the toxic effects of catecholamines. In a large number of randomized, double-blind, placebo- controlled trials, long-term treatment of patients with chronic heart failure with β-adrenergic blockers improves cardiac function, ameliorates symptoms, and reduces the risk of death and hospitalization. The nature and consistency of these benefits have led an increasing number of physicians to conclude that most patients with heart failure should be considered candidates for long-term treatment with these drugs. Analysis of these clinical trials has also raised the possibility that β-blockers might differ from each other. Specifically, might agents that block α1, β1-, and β2-receptors be more effective and better tolerated that agents that act selectively on the β1- receptor? This hypothesis is now being evaluated in a large-scale, long- term, international trial.

AB - Prolonged activation of the sympathetic nervous system in patients with impaired ventricular function exerts adverse effects on the heart and circulation by a variety of mechanisms that are triggered by the interaction of norepinephrine and epinephrine with α1-, β1-, and β2-adrenergic receptors. Drugs that interfere with the actions of the sympathetic nervous system on α- and β-receptors might be expected to antagonize these deleterious effects. β1-receptor blockers have been shown to prevent and reverse many of the structural and functional changes that occur during the progression of heart failure, and β2- and α1-receptor blockade seems to enhance the ability of β1-blockers to prevent the toxic effects of catecholamines. In a large number of randomized, double-blind, placebo- controlled trials, long-term treatment of patients with chronic heart failure with β-adrenergic blockers improves cardiac function, ameliorates symptoms, and reduces the risk of death and hospitalization. The nature and consistency of these benefits have led an increasing number of physicians to conclude that most patients with heart failure should be considered candidates for long-term treatment with these drugs. Analysis of these clinical trials has also raised the possibility that β-blockers might differ from each other. Specifically, might agents that block α1, β1-, and β2-receptors be more effective and better tolerated that agents that act selectively on the β1- receptor? This hypothesis is now being evaluated in a large-scale, long- term, international trial.

UR - http://www.scopus.com/inward/record.url?scp=0031875316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031875316&partnerID=8YFLogxK

M3 - Article

C2 - 9715822

AN - SCOPUS:0031875316

VL - 41

SP - 39

EP - 52

JO - Progress in Cardiovascular Diseases

JF - Progress in Cardiovascular Diseases

SN - 0033-0620

IS - 1 SUPPL.

ER -